LIGAND PHARMACEUTICALS INC

Form 4

March 18, 2015

FORM 4

if no longer

Section 16.

Form 4 or

obligations

Form 5

subject to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

may continue. See Instruction 1(b).

(Print or Type Responses)

(Last)

1. Name and Address of Reporting Person * Berkman Charles S

2. Issuer Name and Ticker or Trading

Symbol

LIGAND PHARMACEUTICALS

INC [LGND]

03/16/2015

3. Date of Earliest Transaction (Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Director

X_ Officer (give title

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

5. Relationship of Reporting Person(s) to

(Check all applicable)

VP, Gen. Counsel & Secretary

10% Owner

_ Other (specify

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Issuer

below)

11119 NORTH TORREY PINES ROAD, SUITE 200

(First)

(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)

(Middle)

LA JOLLA, CA 92037

(City)	(State) ((Zip) Table	e I - Non-D	erivative	Secur	ities Acqu	uired, Disposed of	, or Beneficial	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securities Acquired for (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	or	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	03/16/2015		S	6,000	D	\$ 74.51	25,989	D	
Common Stock	03/16/2015		M	1,134	A	\$ 14.47	27,123	D	
Common Stock	03/16/2015		S	1,134	D	\$ 74.58	25,989	D	
Common Stock	03/16/2015		M	4,130	A	\$ 21.92	30,119	D	
Common Stock	03/16/2015		S	4,130	D	\$ 74.58	25,989	D	

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number out Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour or Number of Shares
Employee Stock Option (right to buy)	\$ 14.47	03/16/2015		M	1,134	<u>(1)</u>	02/09/2022	Common Stock	1,13
Non-Qualified Stock Option (right to buy)	\$ 21.92	03/16/2015		M	4,130	(2)	02/15/2023	Common Stock	4,13

Reporting Owners

Relationships Reporting Owner Name / Address

Director 10% Owner Officer Other

VP, Gen. Counsel & Secretary

Berkman Charles S 11119 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA, CA 92037

Signatures

By: Nishan M. de Silva For: Charles S. 03/18/2015 Berkman

> **Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then **(1)** 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12.

(2)

Reporting Owners 2

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.